Comparative Pharmacology
Head-to-head clinical analysis: ANADROL 50 versus XTRENBO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANADROL 50 versus XTRENBO.
ANADROL-50 vs XTRENBO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anabolic steroid; binds to androgen receptors, increasing protein synthesis and promoting nitrogen retention, leading to muscle growth and erythropoietin production.
XTRENBO (testosterone undecanoate) is an androgen receptor agonist. Testosterone binds to androgen receptors, activating gene transcription that leads to the development and maintenance of male secondary sexual characteristics. It also exerts anabolic effects.
Adults: 50-200 mg orally once daily for 2-6 weeks, then 2-4 weeks off. Not for continuous use.
0.25 mg intramuscularly once daily
None Documented
None Documented
Terminal elimination half-life: 4-6 hours for parent drug; active metabolite 17α-methyl-5α-androstan-3α,17β-diol has half-life ~12-18 hours. Requires multiple daily dosing.
12-18 hours (terminal), requiring twice-daily dosing for sustained serum concentrations.
Primarily renal: 90% as glucuronide and sulfate conjugates; 6% fecal; <3% unchanged.
Primarily renal (70%) as unchanged drug; 20% biliary/fecal; 10% metabolized to inactive glucuronides.
Category C
Category C
Anabolic Steroid
Anabolic Steroid